
|Articles|July 1, 2007
- Volume 0 0
MYLAN SCORES VICTORY IN PATENT BATTLE
Advertisement
The latest round in the legal battle over the marketing of generic omeprazole delayedrelease capsules has been won by Mylan Laboratories Inc. A district court in New York ruled that Mylan's generic version of Prilosec does not infringe on AstraZeneca's patents for the popular heartburn drug. At the same time, however, the court held that generic omeprazole products made by 2 other companies, Canada's Apotex Inc and Impax Laboratories Inc in California, do infringe on AstraZeneca's patents.
Articles in this issue
almost 19 years ago
pharmacy TECHNOLOGY newsalmost 19 years ago
pharmacy TECHNOLOGY productsalmost 19 years ago
health-systems PRODUCT newsalmost 19 years ago
generic times product newsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
A closer look at new FDA actionsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
compounding HOTLINEalmost 19 years ago
Is There Science in Quality?almost 19 years ago
Vaccines: Are You Protected?Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5






































































































































